Biotech focused on developing novel, highly-selective, bispecific ADCs to target unmet need in blood cancer.
BiVictriX has raised €8.8M across 1 funding round from 1 investor, most recently a round in Aug 2021. Based in Alderley Edge, UK; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-08-16 | Other | €8.8M |
| Slater Heelis |
| View deal → |
